 Global molecular hemostatic markers acute myeloid leukemia Patients acute myeloid leukemia hemostatic thrombotic complications intravascular coagulation Previous studies routine coagulation analyses useful information patients study first comprehensive evaluation various aspects hemostatic system population patients acute myeloid leukemia Eighteen patients years age diagnosis relapse Hemostatic studies onset days initiation therapy bone marrow blast counts prothrombin time partial thromboplastin time minor prolongations patients patients measurement platelet-associated markers elevated platelet factor thromboxane normal alpha levels Fibrinolytic markers increase D-dimer tissue plasminogen activator decrease alpha levels Plasminogen plasminogen activator inhibitor fibrinogen levels normal Coagulation markers decrease protein antithrombin III levels elevation thrombin-antithrombin complex pretreatment values hemostatic markers similar values days treatment investigation subclinical activation components hemostatic system hypercoagulable state patients hemorrhagic complications risk and/or thrombosis evident patients significance abnormal levels specific molecular markers hemostasis future application markers clinical evaluations leukemic patients risk coagulation disorders